Skip to main content
SpringerLink
Log in

Pharmakologische Aspekte von Angiotensin-II-Rezeptoren und AT1-Rezeptorantagonisten

  • Chapter
Book cover AT1-Rezeptorblockade

  • 36 Accesses

Zusammenfassung

Die Charakterisierung der ANG-II-Rezeptorsubtypen hat uns mit neuen Werkzeugen ausgestattet, mit denen wir unser Wissen um die verschiedenen Funktionen von ANG II erweitern konnten. Mit der Entwicklung der nicht-peptidergen AT1-Antagonisten, der Sartane, konnte ein neues therapeutisches Prinzip zur Behandlung der Hypertonie in die klinische Praxis eingeführt werden. Die Sartane blockieren den AT1-Rezeptor und bieten dabei hohe therapeutische Sicherheit verbunden mit niedriger Toxizität. Weiterhin konnte für die AT1-Rezeptorantagonisten gezeigt werden, daß sie, ähnlich den ACE-Hemmem, Herz- und Gefäßmorphologie und -funktion verbessern können. Die Mechanismen, die diesen zusätzlichen Wirkungen der AT1-Blocker zugrunde liegen, werden noch nicht vollständig verstanden. Da alle AT1-Antagonisten basierend auf den initial beschriebenen Imidazolderivaten entwickelt wurden und alle über eine hoch selektive Blockade des AT1-Rezeptors wirken, könnte man erwarten, daß sie sich auch klinisch ähnlich verhalten. Dennoch kann man bezüglich ihrer pharmakologischen Eigenschaften und bei einigen der neueren Antagonisten auch bezüglich der chemischen Struktur Unterschiede finden. Inwieweit sich diese Unterschiede tatsächlich auf die klinische Praxis auswirken, wird aber erst mit dem wachsenden Einsatz der AT1-Antagonisten und weiterführenden Studien endgültig zu beantworten sein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anderson GH Jr, Streeten DHP, Dalakas TG (1977) Pressor responses to l-Sar-8-Ala-Ang II (saralasin) in hypertensive subjects. Circ Res 40: 243–250

    Article  CAS  PubMed  Google Scholar 

  2. Bottari SP, Taylor V, King IN, Bogdal S, deGasparo M (1991) Angiotensin IIAT2 receptors do not interact with guanine nucleotide binding proteins. Eur J Pharmacol 207: 157–163

    Article  CAS  PubMed  Google Scholar 

  3. Bottari SP, King IN, Reichlin S, Dahlstroem I, Lydon N, deGasparo M (1992) The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate. Biochem Biophys Res Commun 183 (1): 206–211

    Article  CAS  PubMed  Google Scholar 

  4. Boucher R, Asselin JH, Genest J (1994) A new enzyme leading to direct formation of angiotensin II. Circ Res 34 (Suppl 1): 1203–1209

    Google Scholar 

  5. Bovee KC, Wong PC, Timmermans PBMWM, Thoolen MJMC (1991) Effects of nonpeptide Ang II receptor antagonist DuP 753 on blood ressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 4 (Part 2): 327S-333S

    CAS  PubMed  Google Scholar 

  6. Brechler V, Reichlin S, deGasparo M, Bottari SP (1994) Angiotensin II stimulates protein tyrosine phasphatase activity through a G-protein independent mechanism. Receptors and Channels 2: 89–97

    CAS  PubMed  Google Scholar 

  7. Buisson B, Bottari SP, deGasparo M, Gallo PN, Payet MD (1992) The angiotensin IIAT2 receptor modulates T-type calcium current in non-differentiated NG 108–15 cells. FEBS Lett 309: 161–164

    Article  CAS  PubMed  Google Scholar 

  8. Bumier M, Rutschmann B, Nussberger J et al. (1993) Salt-dependent renal effects of an Ang II antagonist in healthy subjects. Hypertension 22: 339–347

    Article  Google Scholar 

  9. Case DB, Wallace JM, Larach JH (1979) Comparison between saralasin and converting enzyme inhibitor in hypertensive desease. Kidney Int 15: S107-S114

    Google Scholar 

  10. Cazaubon C, Gougat J, Guiraudou P, Broussier D, Lacour C, Rocon A, Galindo G, Barthélémy G, Gautret B, Nisato D (1992) In vitro and in vivo pharmacology of SR47436, an Ang II receptor antagonist. Am J Hypertens 5 (Part 2): 19A-20A

    Google Scholar 

  11. Chiù AT, Dunscomb JH, McCall DE, Benfield P, Baubonis W, Sauer B (1993) Characterization of angiotensin AT la receptor isoform by its ligand binding signature. Regul Pept 44: 141–147

    Article  PubMed  Google Scholar 

  12. Chiù AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists VII. Cellular and biochemical pharmacology of DuP 753, on orally active antihypertensive agent. J Pharmacol Exp Ther 252: 711–718

    PubMed  Google Scholar 

  13. Christ DD (1995) Human plasma protein binding of the Ang II receptor antagonist losartan potassium (DuP753/MK954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 35: 515–520

    Article  CAS  PubMed  Google Scholar 

  14. Criscione L, Bradley WA, Bühlmayer P et al. (1995) Valsartan: prechnical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 13: 230–250

    Article  CAS  Google Scholar 

  15. Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, de Gasparo M (1995) Valsartan, Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13: 230–250

    Article  CAS  Google Scholar 

  16. Criscione L, de Gasparo M, Buchlmayer P, Whitebread S, Ramjoue HP, Wood JM (1993) Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the Ang II ATI-receptor subtype. Br J Pharmacol 110: 761–771

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Darnell JE, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (5164): 1415–1421

    Article  CAS  PubMed  Google Scholar 

  18. De Gasparo M, Whitebread S (1995) Binding of valsartan to mammalian ATI-receptors. Regul Pept 59: 303–311

    Article  PubMed  Google Scholar 

  19. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR (1995) Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25: 14–21

    Article  PubMed  Google Scholar 

  20. Dzau VJ, Gibbons GH, Pratt RE (1991) Molecular mechanisms of vascular renin-angiotensin-system in myointimal hyperplasia. Hypertension 18 (suppl. 2): 100–105

    Google Scholar 

  21. Dzau VJ, Gonzalez D, Kaempfer C, Dubin D, Wintroub BU (1987) Human neutrophils release serine proteases capable of activating prorenin. Circ Res 60: 595–601

    Article  CAS  PubMed  Google Scholar 

  22. Dzau VJ, Sasamura H, Hein L (1993) Heterogeneity of angiotensin synthetic pathways and receptor subtypes; physiological and pharmacological implications. J Hypertens 11 (Suppl 3): S13-S18

    CAS  Google Scholar 

  23. Edwards RM, Aiyar N, Ohlstein EH, Weidley EE, Griffm E, Ezekiel M, Keenan RM, Ruffolo RR Jr, Weinstock J (1992) Pharmacological characterization of the nonpeptide Ang II receptor antagonist, SK & F108566. J Pharmacol Exp Ther 260: 175–181

    CAS  PubMed  Google Scholar 

  24. Eurakawa Y, Kishimoto S, Nishikawa K (1982) Hypotensive imidazole derivatives and hypotensive imidazole-5-acetic acid derivatives. Patents issued to Takeda Chemical Industries Ltd. on July 20, 1982, and October 19, 1982, respectively, U.S. Patents 4,340,598 and 4,355,040. Osaka, Japan

    Google Scholar 

  25. Garrison JC, Johnson DE, Campanile CP (1988) Evidence for the role of phosphorylase kinase, protein kinase C and other Ca2+ sensitive protein kinases in the response of hepatocytes to angiotensin II and vasopressin. J Biol Chem 259: 3283–3292

    Google Scholar 

  26. Goa KL, Wagstaff AJ (1996) Losartan Potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51: 820–84510

    Article  CAS  PubMed  Google Scholar 

  27. Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T (1996) Cardiac and vascular effects of long-term Losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 28: 397–02

    Article  CAS  PubMed  Google Scholar 

  28. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger Th (1995) Chronic angiotensin ATI receptor blockade improves cardiac function and metabolism in SHRSP. Hypertension 25 (3): 27 (abstr.)

    Google Scholar 

  29. Grady EE, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE (1991) Expression of AT2 receptors in the developing rat fetus. J Clin Invest 88 (3): 921–933

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Hübner R, Högemann AM, Sunzel M, Riddel JG (1997) Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11 (Supp 2):S19-S25

    PubMed  Google Scholar 

  31. Kakar SS, Riel KK, Neill JD (1992) Differential expression of angiotensin II receptor subtype mRNAs (AT-lAandAT-lB)in the rat brain. Biochem Biophys Res Commun 185 (2): 688–692

    Article  CAS  PubMed  Google Scholar 

  32. Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD (1992) Angiotensin II type-1 receptor subtype cDNAs: Differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 183: 1090–1096

    Article  CAS  PubMed  Google Scholar 

  33. Kambayashi Y, Bardhan S, Tahahashi K et al. (1993) Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268 (33): 24543–24546

    CAS  PubMed  Google Scholar 

  34. Kang J, Posner P, Sumners C (1994) Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein. Am J Physio 267: C1289-C1397

    Google Scholar 

  35. Kawahara Y, Sunako M, Tsuda T, Fukuzaki H, Fukumoto Y, Takai Y (1988) Angiotensin II induced expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 150: 52–59

    Article  CAS  PubMed  Google Scholar 

  36. Kitami Y, Okura T, Marumoto K, Wakamiya R, Hiwada K (1992) Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. Biochem Biophys Res Commun 188 (1): 446–452

    Article  CAS  PubMed  Google Scholar 

  37. Lafayette RA, Mayer G, Park SK, Meyer TW (1992) Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90: 766–771

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Linz W, Wiemer G, Gohlke P, Unger Th, Schölkens BA (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25–9

    CAS  PubMed  Google Scholar 

  39. Lo MW, Goldberg MR, McCrea JB et al. (1995) Pharmacokinetics of losartan, an Ang II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58: 641–649

    Article  CAS  PubMed  Google Scholar 

  40. Marino MR, Langenbacher KM, Ford NF, Uderman HD (1997) Safety, tolerabihty, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects, (abstract) Scientific meeting of the American Society of Hypertension 1997

    Google Scholar 

  41. Marrero MB, Schieffer B, Paxton WG et al. (1995) Direct stimulation of Jak/STAT pathway by the angiotensin II ATI receptor. Nature 375: 247–250

    Article  CAS  PubMed  Google Scholar 

  42. Martinez F, Schmitt F, Savoiu C, Leenhardt AF, Braoard R, Peronnet P, Lacour B, Grünfeld JP (1994) Effect of SR 47436 (BMS-186295) on renal hemodynamics and on glomerular permselectivity in health humans. J Am Soc Nephrol 5: 607

    Google Scholar 

  43. Meffert S, Stoll M, Unger Th (1995) The AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells in the presence of EGF and NGF. Naunyn-Schmiedeberg’s Arch of Pharmacol 351 (suppl.): abstr. 471

    Google Scholar 

  44. Metsärinne KP, Stoll M, Gohlke P, Paul M, Unger Th (1992) Angiotensin II is antiproliferative for coronary endothelial cells in vitro. Pharm Pharmacol Lett 2: 150–152

    Google Scholar 

  45. Morimoto S, Ogihara T (1994) TCV-116: a new angiotensin II type-1 receptor antagonist. Cardiovasc Drug Rev 12: 153–164

    Article  CAS  Google Scholar 

  46. Mukoyama M, Nakajama M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ (1993) Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268 (33): 24539–24542

    CAS  PubMed  Google Scholar 

  47. Müller P, Cohen T, deGasparo M, Sioufi A, Racinepoon A, Howald H (1994) Ang II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 47: 231–245

    Article  PubMed  Google Scholar 

  48. Nakashima M, Uematsu T, Kosuge K (1992) Pilot study of the uricosuric effect of DuP-753, a new Ang II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42: 333–335

    Article  CAS  PubMed  Google Scholar 

  49. Nakayima M, Horiuchi M, Morishita R, Yamada T, Pratt RE, Dzau VJ (1994) Growth inhibitory function of type 2 angiotensin II receptor: Gain of function study by in vivo gene transfer. Hypertension 24 (3): 37

    Google Scholar 

  50. Nisato D, Cazaubon C, Lacour C, Gougat J, Guiraudou P, Bemhart C, Perreaut P, Breliere JC, LeFur G (1992) Pharmacological properties of SR 47436, a non-peptidic Ang II receptor antagonist. Br J Pharmacol 105: 84P

    Google Scholar 

  51. Nöda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T et al. (1993) Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new nonpeptide All antagonist. Biochem Pharmacol 46: 311–18

    Article  PubMed  Google Scholar 

  52. Obermüller N, Unger Th, Culman J, Gohlke P, Bottari SP (1991) Distribution of angiotensin II receptor subtypes in rat brain nuclei. Neurosci Lett 132: 11–15

    Article  PubMed  Google Scholar 

  53. Ohtawa M, Takayama F, Saitoh K (1993) Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide Ang II receptor antagonist, in humans. Br J Clin Pharmacol 35: 290–297

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K et al. (1997) Candesartan (CV-11974) dissociates slowly from the angiotensin ATI receptor. Eur J Pharmacol 319: 137–146

    Article  CAS  PubMed  Google Scholar 

  55. Pals DT, Mascucci FD, Denning GS, Sipos F, Fessler DC (1971) Role of the pressor action of Ang II in experimental hypertension. Circ Res 29: 673–681

    Article  CAS  PubMed  Google Scholar 

  56. Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G (1996) Comparison of the effects of angiotensin- converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol 4: 19–25

    CAS  PubMed  Google Scholar 

  57. Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A (1994) Effects of the angiotensin II antagonist SR 47436 (BMS-186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens 12: 131

    Google Scholar 

  58. Sandberg K, Ji H, Clark AJL, Shapira H, Catt KJ (1992) Cloning and expression of a novel angiotensin II receptor subtype. J Biol Chem 267 (14): 9455–9458

    CAS  PubMed  Google Scholar 

  59. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H (1994) Comparative effects of chronic angiotensin-converting enzyme inhibition and Angll type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89: 2273–2282

    Article  CAS  PubMed  Google Scholar 

  60. Shibouta Y, Inada Y, Ojima et al. (1993) Pharmacological profile of a highly potently and long-acting angiotensin II receptor antagonist, 2-ethoxy-l-((2’-(lH-tetrazol-5-yl)biphenyl-4-yl)methyl)-lH-benzimida- zole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-l-(cyelohexyloxycarbonyloxy(-ethyl 2-ethoxy-l- ((2’(lH-tetrazol-5-yl)biphenyl-4-yl)methyl)-lH-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 266(1): 114–120

    CAS  PubMed  Google Scholar 

  61. Sica DA, Lo MW, Shaw WC et al. (1995) The pharmacokinetics of losartan in renal insufficiency. J Hypertens 13 (Suppl 1): S49-S52

    CAS  Google Scholar 

  62. Siegl PKS (1993) Discovery of losartan, the first specific non-peptide Ang II receptor antagonist. J Hypertens 11 (Suppl 3): S19–S22

    CAS  Google Scholar 

  63. Smith MC, Barrows S, Meibohm A et al. (1995) The effects of Ang II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Am J Hypertens 8: 1177–1183

    Article  CAS  PubMed  Google Scholar 

  64. Stauss HM, Zhu Y, Redlich T, Adamiak D, Mott A, Persson PB, Unger Th (1994) Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk 1:255–262

    CAS  PubMed  Google Scholar 

  65. Stoll M, Steckelings UM, Bottari SP, Unger Th (1993) Regulation of endothelial growth: role of the angiotensin II AT2-receptor. Circulation 88 (suppl.4, part 2): 1–469 (abstr.)

    Google Scholar 

  66. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger Th (1995) The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95: 651–657

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Stouffer GA, Owens GK (1992) Angiotensin Il-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor ßj.Circ Res 70: 820–828

    CAS  Google Scholar 

  68. Strohmenger HU, Lindner KH, Wienen W, Vogt J (1997) Effects of the ATI-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs Resuscitation 35 (1): 61–8

    Article  CAS  PubMed  Google Scholar 

  69. Timmermans PB, Chiù AT, Herblin WE, Wong PC, Smith RD (1992) Angiotensin II receptor subtypes. Am J Hypertens (suppl 6, ptl): 406–410

    Google Scholar 

  70. Timmermans PBMWM, Wong PC, Chiù AT, Herblin WE, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 32: 135–165

    Google Scholar 

  71. Timmermans PBMWM, Wong PC, Chiù AT, Herblin WE, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD (1993) Ang II receptors and Ang II receptor antagonists. Pharmacol Rev 45: 205–251

    CAS  PubMed  Google Scholar 

  72. Timmermans PBMWM, Wong PC, Chiù AT, Herblin WE (1991) Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 12: 55–61

    Article  CAS  PubMed  Google Scholar 

  73. Tsutsumi K, Saavedra JM (1991) Characterization and development of angiotensin II receptor subtypes (AT 1 and AT2) in rat brain. Amer J Physiol 261: R209-R216

    CAS  PubMed  Google Scholar 

  74. Unger Th, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S, Meffert S, Stoll M, Stroth U, Zhu YZ (1996) Angiotensin receptors. J Hypertens 14 (suppl 5): S95–103

    CAS  Google Scholar 

  75. Urata H, Healy B, Stewart RW, Bumpus EM, Husain A (1990) Ang Il-forming pathways in normal and failing human hearts. Circ Res 66: 883–890

    Article  CAS  PubMed  Google Scholar 

  76. Urata H, Kinoshita A, Misono KS, Bumpus EM, Husain A (1990) Identification of a highly specific chymase as the major angiotensin-II-forming enzyme in the human heart. J Biol Chem 265: 22348–22357

    CAS  PubMed  Google Scholar 

  77. Weinstock J, Keenan RM, Samanen J, Hempel J, Finkelstein JA, Eranz RG, Gaitanopoulos DE, Girard GR, Gleason JG, Hill DT, Morgan TM, Peishoff CE, Aiyar N, Brooks DP, Eredrickson TA, Ohlstein EH, Ruffolo RR Jr, Stack EJ, Sulpizio AC, Weidley EE, Edwards RM (1991) l-(Carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 34: 1514–1517

    Google Scholar 

  78. Wintroub BU, Klickstein LB, Watt KW (1981) A human neutrophil dependent pathway for generation of Ang II. J Clin Invest 68:484–490

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  79. Wong PC, Price WA, Chiù AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of DuP753 — an orally active antihypertensive agent. J Pharmacol Exp Ther 255: 211–217

    CAS  PubMed  Google Scholar 

  80. Wong PC, Price WA, Chiù AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252: 726–732

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie, Christian-Albrechts-Universität, Kiel, Deutschland

    O. Chung & Prof. Dr. med. Thomas Unger

  2. Deutsches Institut für Bluthochdruckforschung, Hiedelberg, Deutschland

    O. Chung & Prof. Dr. med. Thomas Unger

  3. Institut für Pharmakologie, Universität Kiel, Hospitalstr. 4-6, D-24105, Kiel, Deutschland

    Prof. Dr. med. Thomas Unger

Authors
  1. O. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Thomas Unger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für experimentelle und klinische Pharmakologie und Toxikologie, Medizinische Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland

    Peter Dominiak

  2. Abteilung für Pathophysiologie, Zentrum für Innere Medizin, Universitätsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Deutschland

    Gerd Heusch

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt

About this chapter

Cite this chapter

Chung, O., Unger, T. (1999). Pharmakologische Aspekte von Angiotensin-II-Rezeptoren und AT1-Rezeptorantagonisten. In: Dominiak, P., Heusch, G. (eds) AT1-Rezeptorblockade. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-93701-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93701-9_3

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-93702-6

  • Online ISBN: 978-3-642-93701-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation